Cancer Cachexia, Pancreatic Cancer
Conditions
Keywords
pancreas, biobank, quantitative imaging, biomarkers, health disparities
Brief summary
The goal of this study is to partner with individuals known or suspected to have pancreatic cancer to build a biobank dedicated to minimizing disparities and personalizing care for individuals affected by pancreatic cancer. A biobank is a resource that involves collection, processing and storage of blood, other bodily fluids, and tissue.
Detailed description
Doctors, researchers, and patient advocates from numerous institutions throughout the state of Florida have formed a partnership known as the Florida Pancreas Collaborative. The goals of the Florida Pancreas Collaborative team are to find better ways to diagnose and treat pancreatic cancer and improve quality of life. Recent research suggests that pancreatic cancer affects people of various racial and ethnic groups differently, with some groups having more aggressive disease and a poorer prognosis than other groups. In this research study, the investigators want to partner with individuals known or suspected to have pancreatic cancer to build a 'biobank' dedicated to minimizing disparities and personalizing care for individuals affected by pancreatic cancer. A biobank is a valuable resource that involves collection, processing, and storage of blood, other bodily fluids, and tissue (obtained during biopsy or surgery) to improve the investigator's understanding of health and disease. When combined with information and medical images obtained through routine care, the investigators will be able to investigate biological processes that may underlie differences and poor outcomes and target them with more effective therapeutic strategies tailored to the individual.
Interventions
OTHERBlood Sample Collection
Participants will be asked to donate blood at baseline (+/- 30 days of diagnosis date) and at the time of follow-up (approximately 6 months and approximately 12 months after baseline).
At the time of tissue biopsy and surgical resection (if applicable), pancreatic tumor tissue and tissue from site of metastasis will be collected.
OTHERData Collection
Participants will be asked to complete a 3 page screening tool at the time of their in-person clinic visit, as well as questionnaires at baseline and at 6 and 12 months.
Sponsors
H. Lee Moffitt Cancer Center and Research Institute
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* 18 years of age or older. * Patient presents for evaluation at a participating site with a strong clinical suspicion or diagnosis of a pancreatic cancer primary based on symptoms, imaging, biopsy, and/or blood-work and has not had treatment. * Patient self-reports as Non-Hispanic White, African American, or Hispanic. * Able to understand and voluntarily sign the informed consent. * Willing to complete study questionnaire(s) and donate medical images and biological specimens (including tissue and blood) obtained at the time of standard of care procedures (biopsy, surgery, and/or venipuncture) after signing the informed consent document.
Exclusion criteria
* No suspicion or diagnosis of pancreatic cancer. * Has a diagnosis of pancreatic cancer but and has already undergone treatment (which may include surgery, chemotherapy, and/or radiation). * Self-reported race/ethnicity other than Non-Hispanic White, African American, or Hispanic. * Unable to provide informed consent. * Unwilling to complete study questionnaires(s) and/or donate biological specimens
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evidence of Precachexia | Up to 12 months | Cases will be evaluated for precachexia using the following guidelines: Anorexia with \<5% weight loss over past 6 months along with metabolic changes that together indicate precachexia. |
| Evidence of Cachexia | Up to 12 months | Cases will be evaluated for cachexia using the following guidelines: Anorexia with \>5% weight loss over past 6 months, along with metabolic changes that together indicate cachexia. |
| Evidence of Refractory Cachexia | Up to 12 months | Cases will be evaluated for refractory cachexia using the following guidelines: Anorexia \>5% weight loss over 6 months along with specific metabolic changes that together indicate refractory cachexia. |
| Presence of Myopenia | Up to 12 months | Measures of skeletal muscle index (SMI) and psoas muscle index (PMI) for will be used for myopenia assessment. |
| Presence of Visceral Adiposity | Up to 12 months | Using CT scans at the axial L2-L3 level, the following radiologic measures of abdominal adiposity will be obtained: visceral fat area (VFA), subcutaneous fat area (SFA), total abdominal fat (TAF) area, and the VFA to SFA ratio (V/S). The VFA to SFA ratio (V/S) will be calculated with V/S \> 0.4 defined as viscerally obese. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | Up to 24 months | Overall Survival will be defined as time from surgery to death from any cause |
| Progression Free Survival | Up to 24 months | Progression Free Survival will be defined as time from surgery to pancreatic cancer recurrence or death. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORJennifer Permuth, PhD
H. Lee Moffitt Cancer Center and Research Institute
Outcome results
None listed